A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B

Phase 1 Completed 64 enrolled Addpharma Inc.

RandomizedCrossoverOpen-labelTreatment

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-221 in healthy male subjects.

Evaluation	Drug	Modality	Dose	Route
Subject	Atorvastatin	Small molecule	5 mg	Oral
Subject	Ezetimibe	Unknown	10 mg	Oral